Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 57Neoplasm Metastasis 21Carcinoma, Non-Small-Cell Lung 9Stomach Neoplasms 8Brain Neoplasms 8Colorectal Neoplasms 7Triple Negative Breast Neoplasms 4Pancreatic Neoplasms 4Ovarian Neoplasms 4Endometrial Neoplasms 4Salivary Gland Neoplasms 3Recurrence 3Neoplasms 3Esophageal Neoplasms 3Adenocarcinoma 3Prostatic Neoplasms 2Meningeal Carcinomatosis 2HER2-positive Gastric Cancer 2Colonic Neoplasms 2Breast Cancer With Brain Metastasis 2Advanced Solid Tumor 2Advanced Breast Cancer 2Adenocarcinoma Of Esophagus 2Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Urethral Neoplasms 1Unresectable Locally Recurrent Breast Cancer 1

Interventions

trastuzumab deruxtecan 1Injections 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unresectable Locally Recurrent Breast Cancer × trastuzumab deruxtecan × 1 year × Clear all
NCT07497386 2026-05-11

A Trial of Trastuzumab Rezetecan in Unresectable Locally Recurrent/Metastatic Breast Cancer

Jiangsu HengRui Medicine Co., Ltd.

Phase 2 Recruiting
150 enrolled
Breast

Unresectable Locally Recurrent Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡